Kawazoe Tetsuro, Nakanishi Ryota, Ando Koji, Zaitsu Yoko, Kudou Kensuke, Nakanoko Tomonori, Itoh Shinji, Oki Eiji, Yoshizumi Tomoharu
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8588, Japan.
Department of Surgery, Iizuka Hospital, Fukuoka, Japan.
Surg Today. 2025 Sep 9. doi: 10.1007/s00595-025-03125-8.
Liver metastases from colorectal cancer (CRLM) are a major determinant of the prognosis of metastatic colorectal cancer. Although curative resection is recommended for resectable CRLM, recurrence remains a challenge and the criteria for patient selection and repeat resection are still unclear. We conducted this study to evaluate the outcomes of metastatic lesion resection with curative intent (R0 resection), to identify the factors associated with recurrence, and to establish the feasibility of repeat metastasectomy.
This single-center retrospective study analyzed 135 patients with synchronous CRLM, who underwent surgical resection or received chemotherapy between January, 2013 and March, 2023.
R0 resection was achieved in 62 (45.9%), with a median recurrence-free survival of 12.3 months. Recurrence developed in 50 (80.6%) of these patients and 28 underwent repeat R0 resection. Initial R0 resection was associated with significantly improved overall survival (OS; hazard ratio [HR], 0.12; p < 0.01) and repeat R0 resection after recurrence improved survival further (HR, 0.32; p = 0.019). Conversion surgery, performed in 42 of 114 patients (36.8%) initially treated with chemotherapy, was significantly associated with the absence of extrahepatic metastases and H1 liver metastases.
These findings highlight the importance of individualized treatment strategies for optimizing CRLM outcomes.
结直肠癌肝转移(CRLM)是转移性结直肠癌预后的主要决定因素。尽管推荐对可切除的CRLM进行根治性切除,但复发仍是一个挑战,患者选择标准和再次切除标准仍不明确。我们开展本研究以评估根治性切除转移性病灶(R0切除)的结果,确定与复发相关的因素,并确定再次肝转移瘤切除术的可行性。
这项单中心回顾性研究分析了2013年1月至2023年3月期间接受手术切除或化疗的135例同步CRLM患者。
62例(45.9%)实现了R0切除,无复发生存期的中位数为12.3个月。这些患者中有50例(80.6%)出现复发,28例接受了再次R0切除。初次R0切除与总生存期(OS)显著改善相关(风险比[HR],0.12;p<0.01),复发后再次R0切除进一步改善了生存期(HR,0.32;p=0.019)。114例最初接受化疗的患者中有42例(36.8%)进行了转换手术,这与无肝外转移和H1肝转移显著相关。
这些发现凸显了个体化治疗策略对优化CRLM治疗结果的重要性。